MD
Maryland Senate Bill SB355

Maryland 2022 Regular Session

Maryland Senate Bill SB355 Compare Versions

OldNewDifferences
11
22
33 EXPLANATION: CAPITALS INDICATE MAT TER ADDED TO EXISTIN G LAW.
44 [Brackets] indicate matter deleted from existing law.
5- Underlining indicates amendments to bill.
6- Strike out indicates matter stricken from the bill by amendment or deleted from the law by
7-amendment.
85 *sb0355*
96
107 SENATE BILL 355
118 J2, J5, J4 2lr1109
129 SB 828/21 – EHE & FIN
13-By: Senator Lam Senators Lam and Hayes
10+By: Senator Lam
1411 Introduced and read first time: January 21, 2022
1512 Assigned to: Education, Health, and Environmental Affairs and Finance
16-Committee Report: Favorable with amendments
17-Senate action: Adopted
18-Read second time: February 26, 2022
1913
20-CHAPTER ______
14+A BILL ENTITLED
2115
2216 AN ACT concerning 1
2317
2418 HIV Prevention Drugs – Prescribing and Dispensing by Pharmacists and 2
2519 Insurance Requirements 3
2620
2721 FOR the purpose of authorizing pharmacists to prescribe and dispense preexposure 4
2822 prophylaxis and postexposure prophylaxis for HIV prevention to patients under 5
2923 certain circumstances; requiring the Maryland Medical Assistance Program to 6
3024 provide drugs that are approved by the United States Food and Drug Administration 7
3125 for HIV prevention; prohibiting managed care organizations, insurers, nonprofit 8
3226 health service plans, and health maintenance organizations from requiring prior 9
3327 authorization, step therapy, or cost–sharing for preexposure prophylaxis for HIV 10
3428 prevention or postexposure prophylaxis for HIV prevention; and generally relating 11
3529 to HIV prevention drugs. 12
3630
3731 BY repealing and reenacting, with amendments, 13
3832 Article – Health Occupations 14
3933 Section 12–101(x)(1)(xi) and (xii) 15
4034 Annotated Code of Maryland 16
4135 (2021 Replacement Volume) 17
4236
4337 BY adding to 18
4438 Article – Health Occupations 19
4539 Section 12–101(x)(1)(xiii) and 12–514 20
4640 Annotated Code of Maryland 21
4741 (2021 Replacement Volume) 22
42+
43+BY repealing and reenacting, without amendments, 23
44+ Article – Health – General 24
45+Section 15–103(a)(1) 25
46+ Annotated Code of Maryland 26
47+ (2019 Replacement Volume and 2021 Supplement) 27
4848 2 SENATE BILL 355
4949
5050
51-BY repealing and reenacting, without amendments, 1
51+BY repealing and reenacting, with amendments, 1
5252 Article – Health – General 2
53-Section 15–103(a)(1) 3
53+Section 15–103(a)(2)(xvi) and (xvii) 3
5454 Annotated Code of Maryland 4
5555 (2019 Replacement Volume and 2021 Supplement) 5
5656
57-BY repealing and reenacting, with amendments, 6
57+BY adding to 6
5858 Article – Health – General 7
59-Section 15–103(a)(2)(xvi) and (xvii) 8
59+Section 15–102.3(j) and 15–103(a)(2)(xviii) 8
6060 Annotated Code of Maryland 9
6161 (2019 Replacement Volume and 2021 Supplement) 10
6262
6363 BY adding to 11
64- Article – Health – General 12
65-Section 15–102.3(j) and 15–103(a)(2)(xviii) 13
64+ Article – Insurance 12
65+Section 15–856 13
6666 Annotated Code of Maryland 14
67- (2019 Replacement Volume and 2021 Supplement) 15
67+ (2017 Replacement Volume and 2021 Supplement) 15
6868
69-BY adding to 16
70- Article – Insurance 17
71-Section 15–856 18
72- Annotated Code of Maryland 19
73- (2017 Replacement Volume and 2021 Supplement) 20
69+ SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND, 16
70+That the Laws of Maryland read as follows: 17
7471
75- SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND, 21
76-That the Laws of Maryland read as follows: 22
72+Article – Health Occupations 18
7773
78-Article – Health Occupations 23
74+12–101. 19
7975
80-12–101. 24
76+ (x) (1) “Practice pharmacy” means to engage in any of the following activities: 20
8177
82- (x) (1) “Practice pharmacy” means to engage in any of the following activities: 25
78+ (xi) Providing drug therapy management in accordance with § 21
79+19–713.6 of the Health – General Article; [or] 22
8380
84- (xi) Providing drug therapy management in accordance with § 26
85-19–713.6 of the Health – General Article; [or] 27
81+ (xii) Prescribing and dispensing contraceptive medications and 23
82+self–administered contraceptive devices approved by th e U.S. Food and Drug 24
83+Administration; OR 25
8684
87- (xii) Prescribing and dispensing contraceptive medications and 28
88-self–administered contraceptive devices approved by the U.S. Food and Drug 29
89-Administration; OR 30
85+ (XIII) PRESCRIBING AND DISPE NSING PREEXPOSURE 26
86+PROPHYLAXIS AND POST EXPOSURE PROPHYLAXIS MEDICATIONS FOR HIV 27
87+APPROVED BY THE U.S. FOOD AND DRUG ADMINISTRATION . 28
9088
91- (XIII) PRESCRIBING AND DISPE NSING PREEXPOSURE 31
92-PROPHYLAXIS AND POST EXPOSURE PROPHYLAXIS MEDICATIONS FOR HIV 32
93-APPROVED BY THE U.S. FOOD AND DRUG ADMINISTRATION . 33
89+12–514. 29
9490
95-12–514. 34
96- SENATE BILL 355 3
91+ (A) (1) IN THIS SECTION THE F OLLOWING WORDS HAVE THE MEANINGS 30
92+INDICATED. 31
93+
94+ (2) “CDC GUIDELINES FOR POSTE XPOSURE PROPHYLAXIS ” MEANS 32
95+“UPDATED GUIDELINES FOR ANTIRETROVIRAL POSTEXPOSURE PROPHYLAXIS 33
96+AFTER SEXUAL, INJECTION DRUG USE, OR OTHER NONOCCUPATIONAL EXPOSURE 34 SENATE BILL 355 3
9797
9898
99- (A) (1) IN THIS SECTION THE F OLLOWING WORDS HAVE THE MEANINGS 1
100-INDICATED. 2
99+TO HIV–UNITED STATES, 2016” OR ANY SUBSEQUENT GU IDELINES PUBLISHED B Y 1
100+THE FEDERAL CENTERS FOR DISEASE CONTROL AND PREVENTION. 2
101101
102- (2) “CDC GUIDELINES FOR POSTE XPOSURE PROPHYLAXIS ” MEANS 3
103-“UPDATED GUIDELINES FOR ANTIRETROVIRAL POSTEXPOSURE PROPHYLAXIS 4
104-AFTER SEXUAL, INJECTION DRUG USE, OR OTHER NONOCCUPATIONAL EXPOSURE 5
105-TO HIV–UNITED STATES, 2016” OR ANY SUBSEQUENT GU IDELINES PUBLISHED B Y 6
106-THE FEDERAL CENTERS FOR DISEASE CONTROL AND PREVENTION. 7
102+ (3) “CDC GUIDELINES FOR PREEX POSURE PROPHYLAXIS ” MEANS 3
103+“PREEXPOSURE PROPHYLAXIS FOR THE PREVENTION OF HIV INFECTION IN THE 4
104+UNITED STATES–2017 UPDATE: A CLINICAL PRACTICE GUIDELINE” OR ANY 5
105+SUBSEQUENT GUIDELINE S PUBLISHED BY THE F EDERAL CENTERS FOR DISEASE 6
106+CONTROL AND PREVENTION. 7
107107
108- (3) “CDC GUIDELINES FOR PREEX POSURE PROPHYLAXIS ” MEANS 8
109-“PREEXPOSURE PROPHYLAXI S FOR THE PREVENTION OF HIV INFECTION IN THE 9
110-UNITED STATES–2017 UPDATE: A CLINICAL PRACTICE GUIDELINE” OR ANY 10
111-SUBSEQUENT GUIDELINE S PUBLISHED BY THE F EDERAL CENTERS FOR DISEASE 11
112-CONTROL AND PREVENTION. 12
108+ (4) “POSTEXPOSURE PROPHYLA XIS” MEANS ANY DRUG 8
109+COMBINATION APPROVED BY THE U.S. FOOD AND DRUG ADMINISTRATION THAT IS: 9
113110
114- (4) “POSTEXPOSURE PROPHYLA XIS” MEANS ANY DRUG 13
115-COMBINATION APPROVED BY TH E U.S. FOOD AND DRUG ADMINISTRATION THAT I S: 14
111+ (I) USED TO PREVENT HIV INFECTION FOLLOWING AN 10
112+EXPOSURE OR POTENTIA L EXPOSURE TO HIV; AND 11
116113
117- (I) USED TO PREVENT HIV INFECTION FOLLOWING AN 15
118-EXPOSURE OR POTENTIA L EXPOSURE TO HIV; AND 16
114+ (II) ADMINISTERED IN ACCOR DANCE WITH THE CDC, IN THE 12
115+CDC GUIDELINES FOR POSTE XPOSURE PROPHYLAXIS . 13
119116
120- (II) ADMINISTERED IN ACCOR DANCE WITH THE CDC, IN THE 17
121-CDC GUIDELINES FOR POSTE XPOSURE PROPHYLA XIS. 18
117+ (5) “PREEXPOSURE PROPHYLAX IS” MEANS ANY DRUG COMBINATION 14
118+APPROVED BY THE U.S. FOOD AND DRUG ADMINISTRATION THAT I S: 15
122119
123- (5) “PREEXPOSURE PROPHYLAX IS” MEANS ANY DRUG COMBI NATION 19
124-APPROVED BY THE U.S. FOOD AND DRUG ADMINISTRATION THAT I S: 20
120+ (I) PROVIDED TO AN HIV–NEGATIVE PERSON TO P REVENT 16
121+HIV INFECTION; AND 17
125122
126- (I) PROVIDED TO AN HIV–NEGATIVE PERSON TO P REVENT 21
127-HIV INFECTION; AND 22
123+ (II) ADMINISTERED IN ACCOR DANCE WITH THE CDC, IN THE 18
124+CDC GUIDELINES FOR PREEX POSURE PROPHYLAXIS . 19
128125
129- (II) ADMINISTERED IN ACCOR DANCE WITH THE CDC, IN THE 23
130-CDC GUIDELINES FOR PREEX POSURE PROPHYLAXIS . 24
126+ (6) “RYAN WHITE HIV/AIDS PROGRAM” MEANS THE PROGRAM 20
127+ADMINISTERED BY THE FEDERAL HEALTH RESOURCES AND SERVICES 21
128+ADMINISTRATION THAT PROVIDES GRANTS TO PROVIDE CARE AND TREATMENT 22
129+SERVICES TO INDIVIDUALS WITH HIV TO IMPROVE HEALTH OU TCOMES AND 23
130+REDUCE HIV TRANSMISSION AMONG HARD –TO–REACH POPULATIONS . 24
131131
132- (6) “RYAN WHITE HIV/AIDS PROGRAM” MEANS THE PROGRAM 25
133-ADMINISTERED BY THE FEDERAL HEALTH RESOURCES AND SERVICES 26
134-ADMINISTRATION THAT P ROVIDES GRANTS TO PR OVIDE CARE AND TREAT MENT 27
135-SERVICES TO INDIVIDU ALS WITH HIV TO IMPROVE HEALTH OU TCOMES AND 28
136-REDUCE HIV TRANSMISSION AMONG H ARD–TO–REACH POPULATIONS . 29
132+ (B) (1) SUBJECT TO PARAGRAPH (2) OF THIS SUBSECTION , A 25
133+PHARMACIST MAY PRESCRIBE AND DISPENSE UP TO A 30–DAY SUPPLY OF 26
134+PREEXPOSURE PROPHYLA XIS TO A PATIENT IF: 27
137135
138- (B) (1) SUBJECT TO PARAGRAPH (2) OF THIS SUBSECTION , A 30
139-PHARMACIST MAY PRESC RIBE AND DISPENSE UP TO A 30–DAY SUPPLY OF 31
140-PREEXPOSURE PROPHYLA XIS TO A PATIENT IF: 32
136+ (I) THE PATIENT IS HIV NEGATIVE AS DOCUMENT ED BY A TEST 28
137+IN ACCORDANCE WITH P ARAGRAPH (3) OF THIS SUBSECTION ; 29
138+
139+ (II) THE PATIENT COMPLETES A SELF –SCREENING 30
140+ASSESSMENT TOOL AND REPORTS: 31
141141 4 SENATE BILL 355
142142
143143
144- (I) THE PATIENT IS HIV NEGATIVE AS DOCUMENT ED BY A TEST 1
145-IN ACCORDANCE WITH P ARAGRAPH (3) OF THIS SUBSECTION ; 2
144+ 1. NO SIGNS OR SYMPTOMS OF ACUTE HIV INFECTION 1
145+FROM A CHECKLIST OF ACUTE HIV INFECTION SIGNS AND SYMPTOMS; AND 2
146146
147- (II) THE PATIENT COMPLETES A SELF –SCREENING 3
148-ASSESSMENT TOOL AND REPORTS: 4
147+ 2. NOT TAKING ANY CONTRA INDICATED MEDICATION S; 3
149148
150- 1. NO SIGNS OR SYMPTOMS OF ACUTE HIV INFECTION 5
151-FROM A CHECKLIST OF ACUTE HIV INFECTION SIGNS AND SYMPTOMS; AND 6
149+ (III) AT THE TIME THE PREEX POSURE PROPHYLAXIS I S 4
150+DISPENSED, THE PHARMACIST PROVI DES: 5
152151
153- 2. NOT TAKING ANY CONTRA INDICATED MEDICATION S; 7
152+ 1. COUNSELING TO THE PAT IENT ON THE ONGOING USE 6
153+OF PREEXPOSURE PRO PHYLAXIS, INCLUDING EDUCATION REGARDING SIDE 7
154+EFFECTS, SAFETY DURING PREGNA NCY AND BREASTFEEDIN G, ADHERENCE TO 8
155+RECOMMENDED DOSING , AND THE IMPORTANCE O F TIMELY TESTING AND 9
156+TREATMENT , AS APPLICABLE, FOR: 10
154157
155- (III) AT THE TIME THE PREEX POSURE PROPHYLAXIS I S 8
156-DISPENSED, THE PHARMACIST PROVI DES: 9
158+ A. HIV; 11
157159
158- 1. COUNSELING TO THE PAT IENT ON THE ONGOING USE 10
159-OF PREEXPOSURE PROP HYLAXIS, INCLUDING EDUCATION REGARDING SIDE 11
160-EFFECTS, SAFETY DURING PREGNA NCY AND BREASTFEEDIN G, ADHERENCE TO 12
161-RECOMMENDED DOSING , AND THE IMPORTANCE O F TIMELY TESTING AND 13
162-TREATMENT , AS APPLICABLE, FOR: 14
160+ B. RENAL FUNCTION ; 12
163161
164- A. HIV; 15
162+ C. HEPATITIS B; 13
165163
166- B. RENAL FUNCTION ; 16
164+ D. HEPATITIS C; 14
167165
168- C. HEPATITIS B; 17
166+ E. SEXUALLY TRANSMITTED DISEASES; AND 15
169167
170- D. HEPATITIS C; 18
168+ F. PREGNANCY FOR INDIVID UALS OF CHILDBEARING 16
169+CAPACITY; AND 17
171170
172- E. SEXUALLY TRANSMITTED DISEASES; AND 19
171+ 2. ORAL AND WRITTEN NOTI CE TO THE PATIENT TH AT, 18
172+IF THE PHARMACIST HAS DISPENSED A COMBINED 60–DAY SUPPLY TO THE PATIENT, 19
173+THE PATIENT MUST BE SEEN BY A HEALTH CAR E PROVIDER TO RECEIV E ANY 20
174+SUBSEQUENT PRESCRIPT IONS FOR PREEXPOSURE PROPHYLAXIS ; 21
173175
174- F. PREGNANCY FOR INDIVID UALS OF CHILDBEARING 20
175-CAPACITY; AND 21
176+ (IV) THE PHARMACIST RECORD S THE PRESCRIBING AND 22
177+DISPENSING OF THE PR EEXPOSURE PROPHYLAXI S IN ANY ELECTRONIC HEALTH 23
178+RECORD M AINTAINED ON THE PAT IENT BY THE PHARMACI ST; 24
176179
177- 2. ORAL AND WRITTEN NOTI CE TO THE PATIENT TH AT, 22
178-IF THE PHARMACIST HA S DISPENSED A COMBIN ED 60–DAY SUPPLY TO THE PA TIENT, 23
179-THE PATIENT MUST BE SEEN BY A HEALTH CAR E PROVIDER TO RECEIV E ANY 24
180-SUBSEQUENT PRESCRIPT IONS FOR PREEXPOSURE PROPHYLAXIS ; 25
180+ (V) THE PHARMACIST PROVID ES THE PATIENT WITH A COPY OF 25
181+THE RECORD OF THE EN COUNTER THAT INCLUDE S THE PATIENT ’S COMPLETED 26
182+SELF–SCREENING ASSESSMENT TOOL AND THE PREEXPO SURE PROPHYLAXIS 27
183+PRESCRIBED AND DISPENSED OR THE BASIS FOR NOT DISPENSING A PREEXPO SURE 28
184+PROPHYLAXIS ; AND 29
181185
182- (IV) THE PHARMACIST RECORD S THE PRESCRIBING AN D 26
183-DISPENSING OF THE PR EEXPOSURE PROPHYLAXI S IN ANY ELECTRONIC HEALTH 27
184-RECORD MAINTAINE D ON THE PATIENT BY THE PHARMACIST ; 28
185-
186- (V) THE PHARMACIST PROVID ES THE PATIENT WITH A COPY OF 29
187-THE RECORD OF THE EN COUNTER THAT INCLUDE S THE PATIENT ’S COMPLETED 30 SENATE BILL 355 5
188-
189-
190-SELF–SCREENING ASSESSMENT TOOL AND THE PREEXPO SURE PROPHYLAXIS 1
191-PRESCRIBED AND DISPE NSED OR THE BASIS FOR NOT DISPEN SING A PREEXPOSURE 2
192-PROPHYLAXIS ; AND 3
193-
194- (VI) THE PHARMACIST PROVID ES: 4
195-
196- 1. NOTICE TO THE PATIENT ’S PRIMARY CARE PROVI DER 5
197-OF THE ENCOUNTER WIT H THE PATIENT; OR 6
198-
199- 2. IF THE PATIENT DOES N OT HAVE A PRIMARY CA RE 7
200-PROVIDER OR REFUSES TO PROVIDE THE NAME OF A PRIMARY CARE PROVI DER, THE 8
201-PATIENT WITH A LIST OF PHYSICIANS , CLINICS, OR OTHER HEALTH CARE 9
202-PROVIDERS IN THE ARE A, INCLUDING PROVIDERS THAT RECEIVE FUNDING , EITHER 10
203-DIRECTLY OR INDIRECT LY, FROM THE RYAN WHITE HIV/AIDS PROGRAM, TO 11
204-CONTACT REGARDING ONGOIN G CARE FOR PREEXPOSU RE PROPHYLAXIS . 12
205-
206- (2) THE PHARMACIST MAY NO T: 13
207-
208- (I) ALLOW THE PATIENT TO REFUSE OR WAIVE ANY 14
209-CONSULTATION REQUIRE D UNDER PARAGRAPH (1) OF THIS SUBSECTION ; 15
210-
211- (II) PRESCRIBE MORE THAN A COMBINED 60–DAY SUPPLY OF 16
212-PREEXPOSURE PROPHYLA XIS TO THE SAME PATI ENT WITHIN A 2–YEAR PERIOD; OR 17
213-
214- (III) DISPENSE MORE THAN A COMBINED 60–DAY SUPPLY TO A 18
215-PATIENT WITHOUT A PR ESCRIPTION FROM A HE ALTH CARE PROVIDER . 19
216-
217- (3) (I) BEFORE PRESCRIBING AN D DISPENSING A PREEX POSURE 20
218-PROPHYLAXIS TO A PAT IENT UNDER PARAGRAPH (1) OF THIS SUBSECTION , THE 21
219-PHARMACIST SHALL REQ UIRE THE PATIENT TO : 22
220-
221- 1. SUBMIT EVIDENCE OF TH E PATIENT’S NEGATIVE HIV 23
222-TEST RESULT OBTAINED WITHIN THE IMMEDIATE LY PRECEDING 7 DAYS FROM AN 24
223-HIV ANTIGEN/ANTIBODY TE ST OR ANTIBODY –ONLY TEST OR FROM A RAPID, 25
224-POINT–OF–CARE FINGERSTICK BLO OD TEST THAT IS APPR OVED BY THE U.S. FOOD 26
225-AND DRUG ADMINISTRATION ; OR 27
226-
227- 2. SUBMIT TO AN HIV TEST ORDERED BY THE 28
228-PHARMACIST . 29
229-
230- (II) 1. IF A PHARMACIST ORDER S AN HIV TEST FOR A 30
231-PATIENT UNDER SUBPARAGRA PH (I)2 OF THIS PARAGRAPH AN D THE TEST RESULTS 31
232-ARE NOT TRANSMITTED DIRECTLY TO THE PHAR MACIST, THE PHARMACIST SHALL 32
233-VERIFY THE TEST RESU LTS TO THE PHARMACIS T’S SATISFACTION. 33 6 SENATE BILL 355
186+ (VI) THE PHARMACIST PROVID ES: 30 SENATE BILL 355 5
234187
235188
236189
237- 2. IF A PHARMACIST ORDER S AN HIV TEST FOR A 1
238-PATIENT UNDER SUBPARAGRAPH (I)2 OF THIS PARAGRAPH AN D THE PATIENT TESTS 2
239-POSITIVE FOR HIV INFECTION, THE PHARMACIST SHALL REFER THE PATIENT TO A 3
240-HEALTH CARE PROVIDER AND PROVIDE A LIST O F HEALTH CARE PROVID ERS AND 4
241-CLINICS IN THE AREA IN WHICH THE PHARMAC Y IS LOCATED , INCLUDING 5
242-PROVIDERS AND CLINIC S THAT RECEIVE FUNDING , EITHER DIRECTLY OR 6
243-INDIRECTLY, FROM THE RYAN WHITE HIV/AIDS PROGRAM. 7
190+ 1. NOTICE TO THE PATIENT ’S PRIMARY CARE PROVI DER 1
191+OF THE ENCOUNTER WIT H THE PATIENT; OR 2
244192
245- (C) (1) A PHARMACIST MAY PRESC RIBE AND DISPENSE A COMPLETE 8
246-COURSE OF POSTEXPOSU RE PROPHYLAXIS TO A PATIENT IF THE PHARM ACIST: 9
193+ 2. IF THE PATIENT DOES N OT HAVE A PRIMARY CA RE 3
194+PROVIDER OR REFUSES TO PROVIDE T HE NAME OF A PRIMARY CARE PROVIDER , THE 4
195+PATIENT WITH A LIST OF PHYSICIANS , CLINICS, OR OTHER HEALTH CARE 5
196+PROVIDERS IN THE AREA THAT REC EIVE FUNDING , EITHER DIRECTLY OR 6
197+INDIRECTLY, FROM THE RYAN WHITE HIV/AIDS PROGRAM TO CONTACT 7
198+REGARDIN G ONGOING CARE FOR P REEXPOSURE PROPHYLAX IS. 8
247199
248- (I) SCREENS THE PATIENT A ND DETERMINES : 10
200+ (2) THE PHARMACIST MAY NO T: 9
249201
250- 1. THE EXPOSURE TO HIV OCCURRED WITHIN THE 11
251-IMMEDIATELY PRECEDIN G 72 HOURS; AND 12
202+ (I) ALLOW THE PATIENT TO REFUSE OR WAIVE ANY 10
203+CONSULTATION REQUIRE D UNDER PARAGRAPH (1) OF THIS SUBSECTION ; 11
252204
253- 2. THE PATIENT OTHERWISE MEETS THE CLINICAL 13
254-CRITERIA FOR POSTEXP OSURE PROPHYLAXIS CO NSISTENT WITH THE CDC 14
255-GUIDELINES FOR POSTE XPOSURE PROPHYLAXIS ; 15
205+ (II) PRESCRIBE MORE THAN A COMBINED 60–DAY SUPPLY OF 12
206+PREEXPOSURE PROPHYLAXIS TO THE S AME PATIENT WITHIN A 2–YEAR PERIOD; OR 13
256207
257- (II) 1. PROVIDES HIV TESTING THAT IS CLAS SIFIED AS 16
258-WAIVED UNDER THE FED ERAL CLINICAL LABORATORY IMPROVEMENT 17
259-AMENDMENTS OF 1988; OR 18
208+ (III) DISPENSE MORE THAN A COMBINED 60–DAY SUPPLY TO A 14
209+PATIENT WITHOUT A PR ESCRIPTION FROM A HE ALTH CARE PROVIDER . 15
260210
261- 2. EXCEPT AS PROVIDED IN PARAGRAPH (3) OF THIS 19
262-SUBSECTION, OBTAINS THE CONSENT OF THE PATIENT TO SU BMIT TO AN HIV TEST 20
263-CONSISTENT WITH THE CDC GUIDELINES FOR POSTE XPOSURE PROPHYLAXIS ; 21
211+ (3) (I) BEFORE PRESCRIBING AND DISPENSING A PREEXPO SURE 16
212+PROPHYLAXIS TO A PA TIENT UNDER PARAGRAP H (1) OF THIS SUBSECTION , THE 17
213+PHARMACIST SHALL REQ UIRE THE PATIENT TO : 18
264214
265- (III) PROVIDES COUNSELING T O THE PATIENT ON : 22
215+ 1. SUBMIT EVIDENCE OF TH E PATIENT’S NEGATIVE HIV 19
216+TEST RESULT OBTAINED WITHIN THE IMMEDIATE LY PRECEDING 7 DAYS FROM AN 20
217+HIV ANTIGEN/ANTIBODY TEST OR ANT IBODY–ONLY TEST OR FROM A RAPID , 21
218+POINT–OF–CARE FINGERSTICK BLO OD TEST THAT IS APPR OVED BY THE U.S. FOOD 22
219+AND DRUG ADMINISTRATION ; OR 23
266220
267- 1. THE USE OF POSTEXPOSU RE PROPHYLAXIS 23
268-CONSISTENT WITH THE CDC GUIDELINES FOR POSTE XPOSURE PROPHYLAXIS , 24
269-INCLUDING EDUCATION REGARDING SIDE EFFECTS, SAFETY DURING PREGNA NCY 25
270-AND BREASTFEEDING , ADHERENCE TO RECOMME NDED DOSING , AND THE 26
271-IMPORTANCE OF TIMELY TESTING AND TREATMEN T, AS APPLICABLE, FOR HIV AND 27
272-SEXUALLY TRANSMITTED DISEASES; AND 28
221+ 2. SUBMIT TO AN HIV TEST ORDERED BY THE 24
222+PHARMACIST . 25
273223
274- 2. THE AVAILABILITY OF PREEXPOSURE PROPHYLA XIS 29
275-FOR INDIVIDUALS WHO ARE AT SUBSTANTIAL R ISK OF CONTRACTING HIV; AND 30
224+ (II) 1. IF A PHARMACIST ORDER S AN HIV TEST FOR A 26
225+PATIENT UNDER SUBPAR AGRAPH (I)2 OF THIS PARAGRAPH AN D THE TEST RESULTS 27
226+ARE NOT TRANSMITTED DIRECTLY TO THE PHAR MACIST, THE PHARMACIST SHALL 28
227+VERIFY THE TEST RESU LTS TO THE PHARMACIS T’S SATISFACTION. 29
276228
277- (IV) PROVIDES: 31
278- SENATE BILL 355 7
229+ 2. IF A PHAR MACIST ORDERS AN HIV TEST FOR A 30
230+PATIENT UNDER SUBPAR AGRAPH (I)2 OF THIS PARAGRAPH AN D THE PATIENT TESTS 31
231+POSITIVE FOR HIV INFECTION, THE PHARMACIST SHALL REFER THE PATIENT TO A 32 6 SENATE BILL 355
279232
280233
281- 1. NOTICE TO THE PATIENT ’S PRIMARY CARE PROVI DER 1
282-OF THE POSTEXPOSURE PROPHYLAXIS TREATMEN T; OR 2
234+HEALTH CARE PROVIDER AND PROVIDE A LIST O F HEALTH CARE PROVID ERS AND 1
235+CLINICS IN THE AREA IN WHICH TH E PHARMACY IS LOCATE D THAT RECEIVE 2
236+FUNDING, EITHER DIRECTLY OR I NDIRECTLY, FROM THE RYAN WHITE HIV/AIDS 3
237+PROGRAM. 4
283238
284- 2. IF THE PATIENT DOES N OT HAVE A PRIMAR Y CARE 3
285-PROVIDER OR REFUSES TO PROVIDE THE NAME OF A HEALTH CARE PRO VIDER, THE 4
286-PATIENT WITH A LIST OF PHYSICIANS , CLINICS, OR OTHER HEALTH CARE 5
287-PROVIDERS IN THE ARE A, INCLUDING PROVIDERS THAT RECEIVE FUNDING , EITHER 6
288-DIRECTLY OR INDIRECT LY, FROM THE RYAN WHITE HIV/AIDS PROGRAM, TO 7
289-CONTACT REGARDING FO LLOW–UP CARE FOR POSTEXPO SURE PROPHYLAXIS . 8
239+ (C) (1) A PHARMACIST MAY PRESCRIBE AND DISPENSE A COMPLETE 5
240+COURSE OF POSTEXPOSU RE PROPHYLAXIS TO A PATIENT IF THE PHARM ACIST: 6
290241
291- (2) A PHARMACIST MAY NOT A LLOW A PATIENT TO RE FUSE OR WAIVE 9
292-A CONSULTATION REQUI RED UNDER PARAGRAPH (1) OF THIS SUBSECTION . 10
242+ (I) SCREENS THE PATIENT A ND DETERMINES : 7
293243
294- (3) IF THE PATIENT REFUSE S TO CONSENT T O AN HIV TEST UNDER 11
295-PARAGRAPH (1)(II)2 OF THIS SUBSECTION B UT OTHERWISE MEETS T HE CRITERIA 12
296-FOR POSTEXPOSURE PRO PHYLAXIS UNDER THIS SUBSECTION, THE PHARMACIST 13
297-MAY PRESCRIBE AND DI SPENSE POSTEXPOSURE PROPHYLAXIS TO THE P ATIENT. 14
244+ 1. THE EXPOSURE TO HIV OCCURRED WITHIN THE 8
245+IMMEDIATELY PRECEDIN G 72 HOURS; AND 9
298246
299- (D) (1) (I) A PHARMACIST SHA LL COMPLETE A TRAINI NG PROGRAM 15
300-ON THE USE OF PREEXP OSURE PROPHYLAXIS AN D POSTEXPOSURE PROPH YLAXIS 16
301-THAT IS APPROVED BY THE BOARD BEFORE PRESCRIB ING AND DISPENSING 17
302-PREEXPOSURE PROPHYLA XIS OR POSTEXPOSURE PROPHYLAXIS TO A PAT IENT. 18
247+ 2. THE PATIENT OTHERWISE MEETS THE CLINICAL 10
248+CRITERIA FOR POSTEXP OSURE PROPHYLAXIS CO NSISTENT WITH THE CDC 11
249+GUIDELINES FOR POSTEXPOSURE PRO PHYLAXIS; 12
303250
304- (II) THE TRAINING PROGRA M REQUIRED UNDER 19
305-SUBPARAGRAPH (I) OF THIS PARAGRAPH SH ALL INCLUDE INFORMAT ION ABOUT 20
306-FINANCIAL ASSISTANCE PROGRAMS FOR PREEXPO SURE PROPHYLAXIS AND 21
307-POSTEXPOSURE PROPHYL AXIS. 22
251+ (II) 1. PROVIDES HIV TESTING THAT IS CLAS SIFIED AS 13
252+WAIVED UNDER THE FED ERAL CLINICAL LABORATORY IMPROVEMENT 14
253+AMENDMENTS OF 1988; OR 15
308254
309- (2) THE BOARD SHALL CONSULT W ITH THE STATE BOARD OF 23
310-PHYSICIANS, THE STATE BOARD O F NURSING, AND OTHER RELEVANT 24
311-STAKEHOLDERS , INCLUDING THE MARYLAND CENTER FOR HIV CARE SERVICES, 25
312-WHEN DEVELOPING OR A PPROVING TRAINING PR OGRAMS THAT MEET THE 26
313-REQUIREMENTS OF THIS SUBSECTION. 27
255+ 2. EXCEPT AS PROVIDED IN PARAGRAPH (3) OF THIS 16
256+SUBSECTION, OBTAINS THE CONSENT OF THE PATIENT TO SUBMIT TO AN HIV TEST 17
257+CONSISTENT WITH THE CDC GUIDELINES FOR POSTE XPOSURE PROPHYLAXIS ; 18
314258
315- (E) THE BOARD, IN CONSULTATION WITH THE STATE BOARD OF 28
316-PHYSICIANS AND THE STATE BOARD OF NURSING, SHALL ADOPT REGULATI ONS 29
317-ESTABLISHING PROCEDU RES FOR CREATING AND DISSEMINATING A LIST OF 30
318-ENTITIES THAT RECEIV E FUNDING, EITHER DIRECTLY OR I NDIRECTLY, FROM THE 31
319-RYAN WHITE HIV/AIDS PROGRAM. 32
259+ (III) PROVIDES COUNSELING T O THE PATIENT ON : 19
320260
321-Article – Health – General 33
261+ 1. THE USE OF POSTEXPOSU RE PROPHYLAXIS 20
262+CONSISTENT WITH THE CDC GUIDELINES FOR POSTE XPOSURE PROPHYLAXIS , 21
263+INCLUDING EDUCATION REGARDING SIDE EFFEC TS, SAFETY DURING PREGNA NCY 22
264+AND BREASTFEEDING , ADHERENCE TO RECOMME NDED DOSING , AND THE 23
265+IMPORTANCE OF TIMELY TESTING AND TREATMEN T, AS APPLICABLE, FOR HIV AND 24
266+SEXUALLY TRANSMITTED DISEASES; AND 25
322267
323-15–103. 34
324- 8 SENATE BILL 355
268+ 2. THE AVAILABILI TY OF PREEXPOSURE PR OPHYLAXIS 26
269+FOR INDIVIDUALS WHO ARE AT SUBSTANTIAL R ISK OF CONTRACTING HIV; AND 27
270+
271+ (IV) PROVIDES: 28
272+
273+ 1. NOTICE TO THE PATIENT ’S PRIMARY CARE PROVI DER 29
274+OF THE POSTEXPOSURE PROPHYLAXIS TREATMEN T; OR 30
275+
276+ 2. IF THE PATIENT DOES N OT HAVE A PRIMARY CARE 31 SENATE BILL 355 7
325277
326278
327- (a) (1) The Secretary shall administer the Maryland Medical Assistance 1
328-Program. 2
279+PROVIDER OR REFUSES TO PROVIDE THE NAME OF A HEALTH CARE PRO VIDER, THE 1
280+PATIENT WITH A LIST OF PHYSICIANS , CLINICS, OR OTHER HEALTH CARE 2
281+PROVIDERS IN THE AREA THAT REC EIVE FUNDING , EITHER DIRECTLY OR 3
282+INDIRECTLY, FROM THE RYAN WHITE HIV/AIDS PROGRAM TO CONTACT 4
283+REGARDING FOLLOW –UP CARE FOR POSTEXPO SURE PROPHYLAXIS . 5
329284
330- (2) The Program: 3
285+ (2) A PHARMACIST MAY NOT A LLOW A PATIENT TO RE FUSE OR WAIVE 6
286+A CONSULTATION REQUI RED UNDER PARAGRAPH (1) OF THIS SUBSECTION . 7
331287
332- (xvi) Beginning on January 1, 2021, shall provide, subject to the 4
333-limitations of the State budget and § 15–855(b)(2) of the Insurance Article, and as permitted 5
334-by federal law, services for pediatric autoimmune neuropsychiatric disorders associated 6
335-with streptococcal infections and pediatric acute onset neuropsychiatric syndrome, 7
336-including the use of intravenous immunoglobulin therapy, for eligible Program recipients, 8
337-if pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections 9
338-and pediatric acute onset neuropsychiatric syndrome are coded for billing and diagnosis 10
339-purposes in accordance with § 15–855(d) of the Insurance Article; [and] 11
288+ (3) IF THE PATIENT REFUSE S TO CONSENT TO AN HIV TEST UNDER 8
289+PARAGRAPH (1)(II)2 OF THIS SUBSECTION B UT OTHERWISE MEETS T HE CRITERIA 9
290+FOR POSTEXPOSURE PRO PHYLAXIS UNDER THIS SUBSECTION, THE PHARMACIST 10
291+MAY PRESCRIBE AND DISPENSE POSTEXPOSUR E PROPHYLAXIS TO THE PATIENT. 11
340292
341- (xvii) Beginning on January 1, 2022, may not include, subject to federal 12
342-approval and limitations of the State budget, a frequency limitation on covered dental 13
343-prophylaxis care or oral health exams that requires the dental prophylaxis care or oral 14
344-health exams to be provided at an interval greater than 120 days within a plan year; AND 15
293+ (D) (1) (I) A PHARMACIST SHALL COM PLETE A TRAINING PROGRAM 12
294+ON THE USE OF PREEXP OSURE PROPHYLAXIS AN D POSTEXPOSURE PROPH YLAXIS 13
295+THAT IS APPROVED BY THE BOARD BEFORE PRESCRIBING AND DISPENSING 14
296+PREEXPOSURE PROPHYLA XIS OR POSTEXPOSURE PROPHYLAXIS TO A PAT IENT. 15
345297
346- (XVIII) SHALL PROVIDE, SUBJECT TO THE LIMIT ATIONS OF 16
347-THE STATE BUDGET , MEDICALLY APPROPRIAT E DRUGS THAT ARE APP ROVED BY 17
348-THE U.S. FOOD AND DRUG ADMINISTRATION FOR HIV PREVENTION , INCLUDING: 18
298+ (II) THE TRAINING PROGRAM REQUIRED UNDER 16
299+SUBPARAGRAPH (I) OF THIS PARAGRAPH SH ALL INCLUDE INFORMAT ION ABOUT 17
300+FINANCIAL ASSISTANCE PROGRAMS FOR PREEXPO SURE PROPHYLAXIS AND 18
301+POSTEXPOSURE PROPHYL AXIS. 19
349302
350- 1. PREEXPOSURE PROPHYLAX IS; AND 19
303+ (2) THE BOARD SHALL CONSULT W ITH THE STATE BOARD OF 20
304+PHYSICIANS, THE STATE BOARD OF NURSING, AND OTHER RELEVANT 21
305+STAKEHOLDERS , INCLUDING THE MARYLAND CENTER FOR HIV CARE SERVICES, 22
306+WHEN DEVELOPING OR A PPROVING TRAINING PR OGRAMS THAT MEET THE 23
307+REQUIREMENTS OF THIS SUBSECTION. 24
351308
352- 2. POSTEXPOSURE PROPHYLA XIS, AS DEFINED IN § 20
353-12–513 OF THE HEALTH OCCUPATIONS ARTICLE. 21
309+ (E) THE BOARD, IN CONSULTATION WITH THE STATE BOARD OF 25
310+PHYSICIANS AND THE STATE BOARD OF NURSING, SHALL ADOPT REGULATI ONS 26
311+ESTABLISHING PROCEDU RES FOR CREATING AND DISSEMINATING A LIST OF 27
312+ENTITIES THAT RECEIV E FUNDING, EITHER DIRECTLY OR I NDIRECTLY, FROM THE 28
313+RYAN WHITE HIV/AIDS PROGRAM. 29
354314
355- SECTION 2. AND BE IT FURTHER ENACTED, That the Laws of Maryland read 22
356-as follows: 23
315+Article – Health – General 30
357316
358-Article – Health – General 24
317+15–103. 31
359318
360-15–102.3. 25
319+ (a) (1) The Secretary shall administer the Maryland Medical Assistance 32
320+Program. 33
361321
362- (J) THE PROVISIONS OF § 15–856 OF THE INSURANCE ARTICLE APPLY TO 26
363-MANAGED CARE ORG ANIZATIONS IN THE SA ME MANNER AS THEY AP PLY TO 27
364-CARRIERS. 28
322+ (2) The Program: 34 8 SENATE BILL 355
365323
366-Article – Insurance 29
367324
368-15–856. 30
369325
370- (A) (1) IN THIS SECTION THE F OLLOWING WORDS HAVE THE MEANINGS 31
371-INDICATED. 32
326+ (xvi) Beginning on January 1, 2021, shall provide, subject to the 1
327+limitations of the State budget and § 15–855(b)(2) of the Insurance Article, and as permitted 2
328+by federal law, services for pediatric autoimmune neuropsychiatric disorders associated 3
329+with streptococcal infections and pediatric acute onset neuropsychiatric syndrome, 4
330+including the use of intravenous immunoglobulin therapy, for eligible Program recipients, 5
331+if pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections 6
332+and pediatric acute onset neuropsychiatric syndrome are coded for billing and diagnosis 7
333+purposes in accordance with § 15–855(d) of the Insurance Article; [and] 8
334+
335+ (xvii) Beginning on January 1, 2022, may not include, subject to federal 9
336+approval and limitations of the State budget, a frequency limitation on covered dental 10
337+prophylaxis care or oral health exams that requires the dental prophylaxis care or oral 11
338+health exams to be provided at an interval greater than 120 days within a plan year; AND 12
339+
340+ (XVIII) SHALL PROVIDE , SUBJECT TO THE LIMIT ATIONS OF 13
341+THE STATE BUDGET , MEDICALLY APPROPRIAT E DRUGS THAT ARE APP ROVED BY 14
342+THE U.S. FOOD AND DRUG ADMINISTRATION FOR HIV PREVENTION , INCLUDING: 15
343+
344+ 1. PREEXPOSURE PROPHYLAX IS; AND 16
345+
346+ 2. POSTEXPOSURE PROPHYLA XIS, AS DEFINED IN § 17
347+12–513 OF THE HEALTH OCCUPATIONS ARTICLE. 18
348+
349+ SECTION 2. AND BE IT FURTHER ENACTED, That the Laws of Maryland read 19
350+as follows: 20
351+
352+Article – Health – General 21
353+
354+15–102.3. 22
355+
356+ (J) THE PROVISIONS OF § 15–856 OF THE INSURANCE ARTICLE APPLY TO 23
357+MANAGED CARE ORGANIZ ATIONS IN THE SAME M ANNER AS THEY APPLY TO 24
358+CARRIERS. 25
359+
360+Article – Insurance 26
361+
362+15–856. 27
363+
364+ (A) (1) IN THIS SECTION THE FOLLOWING WORDS HAVE THE MEANINGS 28
365+INDICATED. 29
366+
367+ (2) “POSTEXPOSURE PROPHYLA XIS” MEANS ANY DRUG 30
368+COMBINATION APPROVED BY THE U.S. FOOD AND DRUG ADMINISTRATION THAT I S: 31
372369 SENATE BILL 355 9
373370
374371
375- (2) “POSTEXPOSURE PROPHYLA XIS” MEANS ANY DRUG 1
376-COMBINATION APPROVED BY THE U.S. FOOD AND DRUG ADMINISTRATION THAT I S: 2
372+ (I) USED TO PREVENT HIV INFECTION FOLLOWING AN 1
373+EXPOSURE OR A POTENTIAL EXPOS URE TO HIV; AND 2
377374
378- (I) USED TO PREVENT HIV INFECTION FOLLOWING AN 3
379-EXPOSURE OR A POTENT IAL EXPOSURE TO HIV; AND 4
375+ (II) ADMINISTERED IN ACCO RDANCE WITH CDC GUIDELINES 3
376+FOR POSTEXPOSURE PRO PHYLAXIS, AS DEFINED IN § 12–514 OF THE HEALTH 4
377+OCCUPATIONS ARTICLE. 5
380378
381- (II) ADMINISTERED IN ACCO RDANCE WITH CDC GUIDELINES 5
382-FOR POSTEXPOSURE PRO PHYLAXIS, AS DEFINED IN § 12–514 OF THE HEALTH 6
383-OCCUPATIONS ARTICLE. 7
379+ (3) “PREEXPOSURE PROPHYLAX IS” MEANS ANY DRUG COMBI NATION 6
380+APPROVED BY THE U.S. FOOD AND DRUG ADMINISTRATION THAT IS: 7
384381
385- (3) “PREEXPOSURE PROPHYLAX IS” MEANS ANY DRUG COMBI NATION 8
386-APPROVED BY THE U.S. FOOD AND DRUG ADMINISTRATION THAT I S: 9
382+ (I) PROVIDED TO AN HIV–NEGATIVE PERSON TO P REVENT HIV 8
383+INFECTION; AND 9
387384
388- (I) PROVIDED TO AN HIV–NEGATIVE PERSON TO P REVENT HIV 10
389-INFECTION; AND 11
385+ (II) ADMINISTERED IN ACCO RDANCE WITH THE CDC 10
386+GUIDELINES FOR PREEX POSURE PROPHYLAXIS , AS DEFINED IN § 12–514 OF THE 11
387+HEALTH OCCUPATIONS ARTICLE. 12
390388
391- (II) ADMINISTERED IN ACCO RDANCE WITH THE CDC 12
392-GUIDELINES FOR PREEXP OSURE PROPHYLAXIS , AS DEFINED IN § 12–514 OF THE 13
393-HEALTH OCCUPATIONS ARTICLE. 14
389+ (B) (1) EXCEPT AS PROVIDED IN PARAGRAP H (2) OF THIS SUBSECTION , 13
390+THIS SECTION APPLIES TO: 14
394391
395- (B) (1) EXCEPT AS PROVIDED IN PARAGRAPH (2) OF THIS SUBSECTION , 15
396-THIS SECTION APPLIES TO: 16
392+ (I) INSURERS AND NONPROF IT HEALTH SERVICE PL ANS THAT 15
393+PROVIDE COVERAGE FOR PRESCRIPTION DRUGS U NDER INDIVIDUAL , GROUP, OR 16
394+BLANKET HEALTH INSUR ANCE POLICIES OR CON TRACTS THAT ARE ISS UED OR 17
395+DELIVERED IN THE STATE; AND 18
397396
398- (I) INSURERS AND NONPROF IT HEALTH SERVICE PL ANS THAT 17
399-PROVIDE COVERAGE FOR PRESCRI PTION DRUGS UNDER IN DIVIDUAL, GROUP, OR 18
400-BLANKET HEALTH INSUR ANCE POLICIES OR CON TRACTS THAT ARE ISSU ED OR 19
401-DELIVERED IN THE STATE; AND 20
397+ (II) HEALTH MAINTENANCE O RGANIZATIONS THAT PR OVIDE 19
398+COVERAGE FOR PRESCRI PTION DRUGS UNDER IN DIVIDUAL OR GROUP CO NTRACTS 20
399+THAT ARE ISSUED OR D ELIVERED IN THE STATE. 21
402400
403- (II) HEALTH MAINTENANCE O RGANIZATIONS THAT PR OVIDE 21
404-COVERAGE FOR PRESCRI PTION DRUGS UNDER IN DIVIDUAL OR GROUP CONTRACTS 22
405-THAT ARE ISSUED OR D ELIVERED IN THE STATE. 23
401+ (2) THIS SECTION DOES NOT APPLY TO A GRANDFATHERED P LAN, AS 22
402+DEFINED IN § 1251 OF THE AFFORDABLE CARE ACT. 23
406403
407- (2) THIS SECTION DOES NOT APPLY TO A GRANDFATH ERED PLAN, AS 24
408-DEFINED IN § 1251 OF THE AFFORDABLE CARE ACT. 25
404+ (C) AN ENTITY SUBJECT TO TH IS SECTION MAY NOT R EQUIRE PRIOR 24
405+AUTHORIZATION OR STEP THERAPY OR IMPOSE ANY COST –SHARING 25
406+REQUIREMENTS , INCLUDING COPAYMENTS , COINSURANCE , OR DEDUCTIBLES , FOR: 26
409407
410- (C) AN ENTITY SUBJECT TO THIS SECTION MAY NOT REQUIRE PRIOR 26
411-AUTHORIZATION OR STE P THERAPY OR IMPOSE AN Y COST–SHARING 27
412-REQUIREMENTS , INCLUDING COPAYMENTS , COINSURANCE , OR DEDUCTIBLES , FOR: 28
408+ (1) PREEXPOSURE PROPHYLA XIS FOR HIV PREVENTION ; OR 27
413409
414- (1) PREEXPOSURE PROPHYLA XIS FOR HIV PREVENTION ; OR 29
410+ (2) POSTEXPOSURE PROPHYL AXIS FOR HIV PREVENTION . 28
415411
416- (2) POSTEXPOSURE PROPHYL AXIS FOR HIV PREVENTION . 30
417- 10 SENATE BILL 355
412+ (D) AN ENTITY SUBJECT TO THIS SECTION MAY NOT IMPOSE ANY 29
413+COST–SHARING REQUIREMENTS , INCLUDING COPAYMENTS , COINSURANCE , OR 30
414+DEDUCTIBLES , FOR MEDICALLY NECES SARY AND APPROPRIATE SERVICES RELATED 31 10 SENATE BILL 355
418415
419416
420- (D) AN ENTITY SUBJECT TO THIS SECTION MAY NOT IMPOSE ANY 1
421-COST–SHARING REQUIREMENTS , INCLUDING COPAYMENTS , COINSURANCE , OR 2
422-DEDUCTIBLES , FOR MEDICALLY NECESS ARY AND APPROPRIATE SERVICES RELATED 3
423-TO THE USE OF POSTEX POSURE PROPHYLAXIS O R PREEXPOSURE PROPHY LAXIS, 4
424-INCLUDING: 5
417+TO THE USE OF POSTEX POSURE PROPHYLAXIS O R PREEXPOSURE PROPHY LAXIS, 1
418+INCLUDING: 2
425419
426- (1) HIV TESTING; 6
420+ (1) HIV TESTING; 3
427421
428- (2) KIDNEY FUNCTION TEST ING; 7
422+ (2) KIDNEY FUNCTION TEST ING; 4
429423
430- (3) ONGOING FOLLOW –UP AND MONITORING EV ERY 3 MONTHS; 8
424+ (3) ONGOING FOLLOW –UP AND MONITORING EV ERY 3 MONTHS; 5
431425
432- (4) PREGNANCY TESTING ; 9
426+ (4) PREGNANCY TESTING ; 6
433427
434- (5) PROVIDER OFFICE AND TELEHEALTH VISITS FO R PRESCRIBING 10
435-AND MEDICATION MANAG EMENT; 11
428+ (5) PROVIDER OFFICE AND TELEHEALTH VISITS FO R PRESCRIBING 7
429+AND MEDICATION MANAG EMENT; 8
436430
437- (6) SEROLOGIC LABORATORY TESTING FOR HEPATITI S B AND 12
438-HEPATITIS C VIRUSES; 13
431+ (6) SEROLOGIC LABORATORY TESTING FOR HEPATITI S B AND 9
432+HEPATITIS C VIRUSES; 10
439433
440- (7) TESTING FOR OTHER SE XUALLY TRANSMITTED I NFECTIONS, 14
441-INCLUDING THREE –SITE TESTING FOR GON ORRHEA AND CHLAMYDIA ; AND 15
434+ (7) TESTING FOR OTHER SE XUALLY TRANSMITTED I NFECTIONS, 11
435+INCLUDING THREE–SITE TESTING FOR GONORRHEA AND CHLAMY DIA; AND 12
442436
443- (8) VACCINATIONS FOR HEP ATITIS B. 16
437+ (8) VACCINATIONS FOR HEP ATITIS B. 13
444438
445- SECTION 3. AND BE IT FURTHER ENACTED, That Section 2 of this Act shall 17
446-apply to all policies, contracts, and health benefit plans that are not grandfathered plans 18
447-as defined in § 1251 of the Affordable Care Act issued, delivered, or renewed in the State 19
448-on or after January 1, 2023. 20
439+ SECTION 3. AND BE IT FURTHER ENACTED, That Section 2 of this Act shall 14
440+apply to all policies, contracts, and health benefit plans that are not grandfathered plans 15
441+as defined in § 1251 of the Affordable Care Act issued, delivered, or renewed in the State 16
442+on or after January 1, 2023. 17
449443
450- SECTION 4. AND BE IT FURTHER ENACTED, That Section 2 of this Act shall take 21
451-effect January 1, 2023. 22
444+ SECTION 4. AND BE IT FURTHER ENACTED, That Section 2 of this Act shall take 18
445+effect January 1, 2023. 19
452446
453- SECTION 5. AND BE IT FURTHER ENACTED, That, except as provided in Section 23
454-4 of this Act, this Act shall take effect October 1, 2022. 24
447+ SECTION 5. AND BE IT FURTHER ENACTED, That, except as provided in Section 20
448+4 of this Act, this Act shall take effect October 1, 2022. 21
455449